Amgen’s year has been defined by very different headlines, from safety questions around Tavneos to upbeat readouts for drugs like Repatha and IMDELLTRA. Investors who held Amgen over the past year are up 47.7%, including dividends. If you were deciding on 5 November 2025 whether to buy, you had both bullish and bearish analyst cases on the table. Which parts of that earlier record would you have backed to justify this outcome?
The move put Amgen in the middle of this trade. Scan 35 healthcare AI stocks for other companies exposed to it.
The Argument You Would Have Been Weighing On Amgen
The shares cost US$320 at the start of the period, which left Amgen holders choosing between two very different stories about where the business might head next.
On the upbeat side, the bull camp put Fair Value at US$403, a notional price based on its own assumptions, leaning on biosimilars and targeted drugs to drive volume-led growth and margin expansion helped by AI-enabled R&D and frequent new launches.
More cautious investors looked at a Fair Value of US$185 and focused on aging therapies, patent expiries, rising biosimilar competition and tighter drug pricing as risks that could pressure revenue and reduce profit margins over time.
What The Results Changed In The Amgen Argument
Amgen’s Q3 2026 report, with revenue at US$10.4b and net income at US$3.9b, supported the bullish focus on volume strength and higher profitability, as net margin moved from 33.7% to 37.3%. Safety and regulatory blows around Tavneos, and pressure on legacy drugs such as Prolia, kept the more cautious thesis alive. Overall, the evidence cut both ways.
The real hinge here was whether new products and biosimilars could outpace aging therapies and pricing pressure. For any other drug maker, it is useful to watch segment sales mix and reported net margin together to see if fresh launches are offsetting erosion in older franchises.
What Today's Amgen Price Already Assumes
Amgen now trades at US$460, after a 47.7% gain over the past year. The selected Narrative’s Fair Value sits below the current price and frames today’s level as already crediting strong execution across newer cardiometabolic, autoimmune, oncology and biosimilar franchises.
The Narrative’s hook is that execution risk and loss of exclusivity could matter more from here. A buyer at today’s price is effectively assuming newer therapies and biosimilars comfortably outrun policy pressure and biosimilar erosion, so how does the source’s concern around high expectations and pipeline depth weigh on that bet?
"Bearish analysts highlight that Amgen's commercial execution is now widely recognized, which leaves less room for positive surprise if new products or pipeline data do not add substantially to the story. Some also frame the stock as closer to fair value after a strong year to date move, and they question how much upside remains without clearer visibility on future exclusivity challenges and competitive positioning for assets like olpasiran and MariTide."
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all
Find Your Own Contrarian Opportunity
You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.
- Company 1 - 49% below our estimate - turn long term optical and solar contracts into higher margin manufacturing volumes and products.
- Company 2 - 45% below our estimate - expand protective film manufacturing while shifting more activity into higher margin service channels.
- Company 3 - 28% below our estimate - grow a low cost digital banking platform as customers deepen usage and credit relationships.
That is three of the list. See the full list of 42 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com